← back to search

Tracy L. McGregor

Vanderbilt University · US
Area of research
Pulmonary and Respiratory Medicine · Pathology and Forensic Medicine
Research interest
Research interests include Kidney Stones and Urolithiasis Treatments, Biomedical Research and Pathophysiology, Porphyrin Metabolism and Disorders, and Chemotherapy-induced organ toxicity mitigation.
h-index
26
citations
2,779
works
59
NIH funding
primary concept
Medicine
email

Recent publications

Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial
American Journal of Kidney Diseases 2022cited by 81position: middledoi
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial
Pediatric Nephrology 2022cited by 44position: middledoi
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
New England Journal of Medicine 2021cited by 492position: middledoi
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1
Clinical Journal of the American Society of Nephrology 2021cited by 79position: middledoi
Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children
Genetics in Medicine 2021cited by 74position: middledoi
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1
Kidney International Reports 2021cited by 31position: middledoi
End Points for Clinical Trials in Primary Hyperoxaluria
Clinical Journal of the American Society of Nephrology 2020cited by 80position: middledoi
Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria
eLife 2020cited by 62position: firstdoi
LB002ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Nephrology Dialysis Transplantation 2020cited by 21position: middledoi
Idiopathic subglottic stenosis is associated with activation of the inflammatory IL‐17A/IL‐23 axis
The Laryngoscope 2016cited by 94position: middledoi
Molecular analysis of idiopathic subglottic stenosis for <i>Mycobacterium</i> species
The Laryngoscope 2016cited by 62position: middledoi
Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study
The Lancet 2015cited by 141position: middledoi
Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between
The American Journal of Human Genetics 2014cited by 376position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

John C. Lieske · Mayo Clinic7 papers (2020–2022)Jaap W. Groothoff · Amsterdam Neuroscience6 papers (2020–2022)Yaacov Frishberg · University of Wisconsin–Madison6 papers (2020–2022)Daniella Magen · Technion – Israel Institute of Technology6 papers (2020–2022)Hadas Shasha‐Lavsky · Bar-Ilan University5 papers (2020–2022)John M. Gansner · Alnylam Pharmaceuticals (United States)5 papers (2020–2022)David J. Sas · Mayo Clinic4 papers (2020–2022)Eva Šimková · Al Jalila Foundation4 papers (2020–2022)Marianne T. Sweetser · Alnylam Pharmaceuticals (United States)3 papers (2021–2022)Kristin Meliambro · Mount Sinai Health System3 papers (2020–2021)Jiandong Lu · Guangzhou University of Chinese Medicine3 papers (2020–2021)Georges Deschênes · Institut des Maladies Génétiques Imagine3 papers (2020–2021)Michael J. Koren · National Health and Medical Research Council3 papers (2020–2021)Pierre Cochat · Institut des Maladies Génétiques Imagine3 papers (2020–2021)Anne‐Laure Sellier‐Leclerc · Inserm3 papers (2021–2022)Jeffrey M. Saland · Mount Sinai Hospital3 papers (2020–2021)Pushkal Garg · Alnylam Pharmaceuticals (United States)3 papers (2020–2021)Sander F. Garrelfs · Emma Kinderziekenhuis3 papers (2020–2021) · 3 papers (2021–2022)Shabbir H. Moochhala · The Royal Free Hospital3 papers (2020–2021)